ω-3 fatty acid differentially modulated serum levels of IGF1 and IGFBP3 in men with CVD: A randomized, double-blind placebo-controlled study

We assessed the effect of a 2-year supplementation with a highly concentrated docosahexaenoic acid (DHA) product with antioxidant activity on non-proliferative diabetic retinopathy (NPDR) in a randomized double-blind placebo-controlled study. A total of 170 patients with diabetes were randomly assigned to the DHA group (n = 83) or the placebo group (n = 87). NPDR was diagnosed using non-contact slit lamp biomicroscopy examination, and classified into mild, moderate, and severe stages. Patients in the DHA group received a high rich DHA triglyceride (1050 mg/day) nutritional supplement, and those in the placebo group received olive oil capsules. The percentages of mild NPDR increased from 61.7% at baseline to 75.7% at the end of the study in the DHA group, and from 61.9% to 73.1% in the placebo group. Moderate NPDR stages decreased from 35.1% at baseline to 18.7% at the end of the study in the DHA group, and from 36.8% to 26.0% in the placebo group. In the DHA group, there were five eyes with severe NPDR at baseline, which increased to one more at the end of the study. In the placebo group, of two eyes with severe NPDR at baseline, one eye remained at the end of the study. Changes in visual acuity were not found. There were improvements in the serum levels of HbA1c in both groups, but significant differences between the DHA and the placebo groups were not found. In this study, the use of a DHA triglyceride nutraceutical supplement for 2 years did not appear to influence the slowing of the progression of NPDR.

Download Full-text

The effect of antioxidants/N-3 fatty acids supplementation on the plasma phospholipid fatty acid pattern and disease activity in patients with Crohn's disease in a double blind placebo controlled study

Gastroenterology ◽

10.1016/s0016-5085(98)84007-9 ◽

1998 ◽

Vol 114 ◽

pp. A984

Author(s):

B.J. Geerling ◽

A.C. van Houwelingen ◽

R.W. Stockbrügger ◽

R-J.M. brummer

Keyword(s):

Fatty Acids ◽

Fatty Acid ◽

Disease Activity ◽

Phospholipid Fatty Acid ◽

Fatty Acid Pattern ◽

Plasma Phospholipid ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Plasma Phospholipid Fatty Acid

Download Full-text

The effects of polyphenol-rich chokeberry juice on fatty acid profiles and lipid peroxidation of active handball players: results from a randomized, double-blind, placebo-controlled study

Canadian Journal of Physiology and Pharmacology ◽

10.1139/cjpp-2015-0575 ◽

2016 ◽

Vol 94 (10) ◽

pp. 1058-1063 ◽

Cited By ~ 9

Author(s):

Snjezana Petrovic ◽

Aleksandra Arsic ◽

Marija Glibetic ◽

Nikola Cikiriz ◽

Vladimir Jakovljevic ◽

...

Keyword(s):

Fatty Acids ◽

Fatty Acid ◽

Phospholipid Fatty Acid ◽

Plasma Phospholipid ◽

Controlled Study ◽

Fatty Acid Profiles ◽

Double Blind ◽

Double Blind Placebo ◽

Intensive Training ◽

Chokeberry Juice

The effect of polyphenol-rich chokeberry juice consumption on plasma phospholipid fatty acid profiles of 32 active male and female handball players was examined. This randomized, double-blind, placebo-controlled study was conducted during the preparatory training in a closed campus, where 18 players (8 males, 10 females) consumed 100 mL of chokeberry juice, while 14 players (7 males, 7 females) consumed placebo. Lipid status, glucose, thiobarbituric acid reactive substances (TBARS), and percentages of fatty acids were assessed at baseline and at the end of the study. Consumption of chokeberry juice induced decreases of C18:1n-9 and C18:3n-3 in men, but no changes in female players. However, placebo-controlled groups had reduced proportions of mono- (C16:1n-7, C18:1n-7) and polyunsaturated fatty acids (PUFAs: C18:3n-3, C20:5n-3, and C22:4n-6) in males, as well as n-6 PUFAs and total PUFAs in females after consumption. These results indicate that chokeberry juice had a weak impact on attenuating the effect of intensive training in active handball players.

Download Full-text

DELAYED OMEGA-3 FATTY ACID SUPPLEMENTS IN RENAL TRANSPLANTATION A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

Transplantation Journal ◽

10.1097/00007890-199502000-00008 ◽

1995 ◽

Vol 59 (3) ◽

pp. 352-356 ◽

Cited By ~ 30

Author(s):

WILLIAM M. BENNETT ◽

CHARLES B. CARPENTER ◽

MICHAEL E. SHAPIRO ◽

TERRY B. STROM ◽

DEBORAH HEFTY ◽

...

Keyword(s):

Fatty Acid ◽

Renal Transplantation ◽

Controlled Study ◽

Omega 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Omega 3 Fatty Acid

Download Full-text

A Double-Blind, Placebo-Controlled Study of the Omega-3 Fatty Acid Docosahexaenoic Acid in the Treatment of Major Depression

American Journal of Psychiatry ◽

10.1176/appi.ajp.160.5.996 ◽

2003 ◽

Vol 160 (5) ◽

pp. 996-998 ◽

Cited By ~ 232

Author(s):

Lauren B. Marangell ◽

James M. Martinez ◽

Holly A. Zboyan ◽

Barbara Kertz ◽

H. Florence Seung Kim ◽

...

Keyword(s):

Fatty Acid ◽

Major Depression ◽

Docosahexaenoic Acid ◽

Controlled Study ◽

Omega 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Omega 3 Fatty Acid

Download Full-text

The effect of antioxidants/n-3 fatty acids supplementation on the plasma phospholipid fatty acid pattern and disease activity in patients with Crohnʼs disease in a double blind placebo controlled study

European Journal of Gastroenterology & Hepatology ◽

10.1097/00042737-199812000-00094 ◽

1998 ◽

Vol 10 (12) ◽

pp. A24

Author(s):

B. J. Geerling ◽

A. C. van Houwelingen ◽

R. W. Stockbrügger ◽

R. -J.M. Brummer

Keyword(s):

Fatty Acids ◽

Fatty Acid ◽

Disease Activity ◽

Phospholipid Fatty Acid ◽

Fatty Acid Pattern ◽

Plasma Phospholipid ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Plasma Phospholipid Fatty Acid

Download Full-text

Nutritional Approaches to the Treatment of Premenstrual Syndrome

Nutrition and Health ◽

10.1177/026010608300200410 ◽

1983 ◽

Vol 2 (3-4) ◽

pp. 203-209 ◽

Cited By ~ 2

Author(s):

M. G. Brush

Keyword(s):

Fatty Acid ◽

Premenstrual Syndrome ◽

Preliminary Evidence ◽

Controlled Study ◽

Complete Relief ◽

Vitamin B ◽

Gamma Linolenic Acid ◽

Double Blind ◽

Evening Primrose ◽

Double Blind Placebo

The use of non-drug approaches to the treatment of premenstrual syndrome (PMS) is reviewed. Pyridoxine (vitamin B6) in doses of 40–100 mg twice daily is now widely used, especially in less severe cases. Current views on the mechanisms involved are described. Recent work on the use of the essential fatty acid, gamma-linolenic acid, (2–3 g oil of evening primrose per day) has shown encouraging preliminary responses, and a double-blind placebo controlled study is in progress. Other nutritional approaches can be supportive, especially in milder cases but are unlikely to provide complete relief. Preliminary evidence suggests that certain allergies may deteriorate premenstrually, therefore some premenstrual benefits may be gained by identifying and avoiding the relevant substances.

Download Full-text

Abstract 11889: Phase Ib Study of Icosabutate, a Novel Structurally Enhanced Fatty Acid, in Subjects With Hypercholesterolemia

Circulation ◽

10.1161/circ.130.suppl_2.11889 ◽

2014 ◽

Vol 130 (suppl_2) ◽

Author(s):

Yan Qin ◽

Jonas Hallén ◽

Tore Skjæret ◽

Erling Odden ◽

David Fraser ◽

...

Keyword(s):

Fatty Acid ◽

Total Cholesterol ◽

Lipid Lowering ◽

Controlled Study ◽

Double Blind ◽

Apo B ◽

Double Blind Placebo ◽

Phase Ib ◽

Mixed Dyslipidemia ◽

Secondary Screening

Introduction: Icosabutate, an orally active structurally enhanced fatty acid (SEFA), has demonstrated reductions in triglycerides (TG) and cholesterol in several rodent models of dyslipidemia and diabetes. In clinical single and multiple ascending dose studies, icosabutate was well tolerated and significantly lowered LDL-C, non-HDL-C, and TG in subjects with mixed dyslipidemia. This phase 1b study explored the lipid-lowering effects of icosabutate in subjects with hypercholesterolemia. Methods: This was a randomized, double-blind, placebo-controlled study. Subjects with hypercholesterolemia treated with a statin for at least 3 months were screened. Statins were temporarily discontinued for at least 28 days prior to dosing and for the duration of the study. To qualify for the study, subjects were required to have an LDL-C ≥ 2.5 mmol/L (97 mg/dL) at the secondary screening visit and an increase in LDL-C of at least 20 % between the primary and secondary screening. Twenty four subjects were randomized to icosabutate 600 mg once daily or matching placebo in a 3:1 fashion and treated for 28 days. Safety and pharmacodynamics were evaluated. Results are reported as placebo-adjusted median percentage change from baseline (average of visit 2-4) to 24 hours after last dose (day 29). Results: Six subjects received placebo and 18 subjects received icosabutate. Median baseline lipid values (mg/dL) placebo/ icosabutate: TC: 270 and 240; LDL-C: 174 and 166; and TG: 204 and 168. Compared to placebo, icosabutate reduced total cholesterol (17.4 %, p < 0.05), LDL-C (29.3 %, p<0.05), non-HDL-C (25.4 %, p<0.05), and apo B (22.8 %, p< 0.05). There was a non-significant increase in HDL-C. TG reductions were not statistically significant (12.6 %, ns), but both placebo and icosabutate subjects experienced large reductions from baseline (29 % versus 42 %). Conclusions: In this randomized, double-blind, placebo-controlled phase Ib study in subjects with hypercholesterolemia, icosabutate demonstrated placebo-adjusted reductions in total cholesterol, LDL-C, non-HDL-C, and apo B. TG levels were also substantially reduced, but not statistically significant in placebo-adjusted analyses.

Download Full-text